Key result
Intravenous doxorubicin administration in Ren-2 transgenic rats induced a severe model of heart failure with reduced ejection fraction and nephrotic syndrome, resulting in 16% survival at 10 weeks compared to 89% in controls.
Why the study?
Current treatments are less effective for anthracycline-induced HFrEF, requiring appropriate animal models to thoroughly understand the pathophysiology and develop new therapeutic approaches.
Population
Ren-2 transgenic rats
Comparison
DOXO via five intravenous injections (cumulative dose 10 mg/kg BW)
Design
Animal model characterization study
Authors
Loading...
May guide new models of anthracycline HFrEF; leaves open clinical translation pending validation.
Absolute Event Rate: 16% vs 89%
p-value: p=<0.0001
The DOXO-treated Ren-2 transgenic rat model adequately mimics chemotherapy-induced HFrEF and cardiorenal syndrome, providing a useful preclinical model for future therapeutic research.
Gawryś et al. (2024) studied Chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome. Doxorubicin vs. Saline was evaluated on Survival at 10 weeks post-treatment (p=<0.0001). Intravenous doxorubicin administration in Ren-2 transgenic rats induced a severe model of heart failure with reduced ejection fraction and nephrotic syndrome, resulting in 16% survival at 10 weeks compared to 89% in controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: